Maryland's Price Cap on Ozempic: What You Need to Know
Maryland's Prescription Drug Affordability Board has taken a landmark step by placing an upper payment limit on Ozempic, a widely used Type 2 diabetes medication. This is only the second time the board has set such a cap, signaling a new era of drug price regulation. Below, we break down what this means for patients, the state, and the future of drug pricing.
What exactly did the Maryland board decide about Ozempic?
The Maryland Prescription Drug Affordability Board voted to establish an upper payment limit for Ozempic, a treatment for Type 2 diabetes. Starting in January 2027, the price for a 30-day supply will be capped at $274. This cap applies to purchases by state and local governments, and the board estimates it will save Maryland $5.8 million annually. The board functions like a utility commission, overseeing drug costs to make them more affordable for public health programs.
Why did the board target Ozempic specifically?
Ozempic was chosen because of its high cost and widespread use among Marylanders with Type 2 diabetes. The medication often carries a list price well above $800 per month, making it a major expense for the state's health plans. By capping the price, the board aims to reduce financial strain on public budgets while ensuring patients retain access to this crucial drug. The decision aligns with the board's mission to address excessive drug prices that burden both taxpayers and patients.
How was the $274 price cap determined?
The cap was benchmarked against the maximum fair price paid by Medicare, according to Andrew York, executive director of the Maryland board. This approach ensures the state doesn't pay more than what the federal government considers reasonable for the same drug. The board conducted an analysis of Ozempic's average sales price, rebates, and discounts to arrive at the $274 figure. This method aims to balance affordability with sustainable market dynamics for manufacturers.
When will the price cap take effect and what happens later?
The upper payment limit will take effect in January 2027 for state and local government purchases. Looking ahead, the board plans to expand its authority starting in 2028 to set limits on high-cost drugs purchased by all Marylanders in the commercial insurance market. This two-phase approach gives stakeholders time to adjust while gradually broadening the scope of affordability measures across the state.
Will other drugs face similar price caps in Maryland?
Yes, this is the second drug the board has targeted. While Ozempic is the latest, the board has already capped prices on another high-cost medication earlier in the year. By 2028, the board will have the power to set upper payment limits on any drug it deems excessively priced in the commercial market. This means more medications could face caps, especially those for chronic conditions like diabetes, heart disease, or cancer where costs are skyrocketing.
How much money will Maryland save and who benefits?
The board estimates the Ozempic cap alone will save $5.8 million per year for state and local governments. These savings come directly from lowering the price paid by Medicaid, state employee health plans, and other public programs. Ultimately, taxpayers benefit because fewer dollars are spent on drug costs, and patients may see lower copays or premiums if savings are passed down. The board also expects that capping Ozempic will signal to other states and health plans that aggressive cost controls are feasible and effective.